Antimicrobial (Susceptibility, % of isolates) | penAmosaic allele | A501 altered PBP2 allele | mtrR promoter (A-deletion/T-insertion) | MtrR coding region (G45D) | penB (alterations in G101/A102) | gyrA (alterations in S91 and D95) | parC (alterations in D86, S87, S88, E91 and A92) |
---|---|---|---|---|---|---|---|
Ceftriaxone (S, 100%) | Nonea | Nonea | 42%/4.6%b | 11% | D/G (26%), G/S (20%), K/D (18%), K/N (9.2%), N/D (6.2%), K/G (4.6%), G/N (4.6%), N/G (1.5%), G/G (1.5%) | ND | ND |
Cefixime (S, 100%) | Nonea | Nonea | 42%/4.6%b | 11% | D/G (26%), G/S (20%), K/D (18%), K/N (9.2%), N/D (6.2%), K/G (4.6%), G/N (4.6%), N/G (1.5%), G/G (1.5%) | ND | ND |
Ciprofloxacin (R, 93.8%) | ND | ND | 44%/4.9%b | 11% | D/G (28%), G/S (20%), K/D (15%), K/N (9.8%), N/D (6.6%), K/G (4.9%), G/N (4.9%), N/G (1.6%), G/G (1.6%) | S91F (100%), | D86N (3.3%), S87N (4.9%), S87I (1.6%), S87R (1.6%), E91G (36%), E91K (15%), E91Q (4.9%) |
D95N (46%), D95G (41%), D95A (10%), D95Y (1.6%) | |||||||
Ciprofloxacin (I, 6.2%) | ND | ND | None | None | K/D (75%), G/S (25%) | S91F (100%) | None |
D95G (100%) |